Lumira Ventures today announced the first closing of Lumira Ventures V, LP ("Fund V"), its latest healthcare venture capital fund dedicated to building transformative biotechnology and medical technology companies across North America. Together with three strategic funds managed by the firm, this closing represents the seventh investment fund established by Lumira. With a target final size of US$200 million (C$275 million), Fund V has already completed its first investment, a US$52 million Series B financing for a pre-commercial-stage medical device company.
